
    
      -  To define the maximum tolerated dose(MTD) and the recommended phase 2 dose (RP2D)

        -  To investigate the pharmacokinetic profile of TY-9591 and its metabolites after single
           then multiple doses of TY-9591 administered orally once daily

        -  To evaluate the anti-cancer activity of TY-9591 in NSCLC patients with EGFR
           mutation(ORR、PFS、DoR、DCR、and CBR)
    
  